Intellia Therapeutics, Inc.NASDAQ: NTLA

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

· Issued by Intellia Therapeutics, Inc. via GlobeNewswire

Summary by 6ix AI

Intellia Therapeutics, a biopharmaceutical company working on CRISPR gene editing, awarded stock grants (restricted stock units, or rights to receive shares in the future) to eight new employees on October 1, 2026 as an incentive to join the company, under its 2024 Inducement Plan, as amended.

Key details

  • The time-based restricted stock units cover an aggregate of 44,450 shares of Intellia's common stock, with one-third vesting annually over three years.
  • The awards were made outside Intellia's stockholder-approved equity plans and were approved by its compensation committee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The 2024 Inducement Plan was initially adopted by Intellia's board of directors in June 2024.

What’s still pending

  • Vesting is subject to each employee's continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2

Watch Intellia Therapeutics' latest callIntellia Therapeutics (NASDAQ:NTLA) Q2 2026 Earnings Call · Replay · Aug 6Read the transcript of Intellia Therapeutics (NASDAQ:NTLA) Q2 2026 Earnings Call

Intellia Therapeutics, Inc.

CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on October 1, 2026, it awarded inducement grants to eight new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 44,450 shares of Intellia's common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee's continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia's stockholder-approved equity incentive plans pursuant to Intellia's 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by Intellia's compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company's mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
[email protected]

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
[email protected]

This press release was published by a CLEAR® Verified individual.

Intellia Therapeutics, Inc. on 6ix

Earlier from Intellia Therapeutics

Later from Intellia Therapeutics

All Intellia Therapeutics news releases